Counterpoint Mutual Funds LLC Purchases Shares of 156,439 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Counterpoint Mutual Funds LLC acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 156,439 shares of the company’s stock, valued at approximately $727,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GDRX. Versor Investments LP bought a new position in shares of GoodRx in the fourth quarter worth $54,000. Verus Capital Partners LLC bought a new position in GoodRx in the 4th quarter valued at about $55,000. Steward Partners Investment Advisory LLC acquired a new position in GoodRx during the 4th quarter valued at about $56,000. Aigen Investment Management LP bought a new stake in shares of GoodRx during the 4th quarter worth about $62,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth approximately $73,000. 63.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GDRX has been the subject of a number of research analyst reports. Mizuho began coverage on shares of GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target for the company. Citigroup decreased their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Wells Fargo & Company decreased their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.18.

GoodRx Price Performance

NASDAQ GDRX opened at $4.42 on Monday. The firm has a market cap of $1.70 billion, a P/E ratio of -147.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The stock’s 50-day moving average is $4.72 and its two-hundred day moving average is $5.51. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.